CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 90 target
Drug / intervention
Anlotinib +2 moredrug
Likely dose
Anlotinib 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06222944
NCT06222944Phase 2Not Yet Recruiting
CompareCT.gov

A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Peking University·interventional·Posted Jan 25, 2024·Updated Jan 25, 2024

In Brief

A Phase 2 clinical trial evaluating Anlotinib, TQB2450, and 1 other intervention for Gastric Cancer and Adenocarcinoma of Esophagogastric Junction. Not yet recruiting, targeting 90 participants across 1 site.

Detailed Summary

This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib, TQB2450 (a PD-L1 inhibitor), and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who have failed the previous treatment with Claudin18.2 (CLDN18.2)-related regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Adenocarcinoma of Esophagogastric Junction
CountriesChina
CollaboratorsChia Tai Tianqing Pharmaceutical Group Co., Ltd.

Timeline

Phase 2Not Yet Recruiting
202420252026
First PostedJan 25, 2024
Enrollment StartFeb 25, 2024
Primary CompletionAug 25, 2025
Study CompletionAug 25, 2026
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.4 years ago

Interventions

Anlotinibdrug

Anlotinib: 12mg PO, QD, D1-14, Q3W;

TQB2450drug

TQB2450: 1200 mg, IV, D1, Q3W

Albumin-Bound Paclitaxeldrug

125mg/m2 IV D1,8，Q3W